Treatment of atopic dermatitis with dupilumab: experience from a tertiary referral centre

Abstract

The effectiveness and safety of dupilumab treatment in a real-life clinical setting are comparable to that of phase 3 clinical trials. LDH is suggested as a potential serological marker predictive of treatment response.